Navigation Links
New TGen, Virginia G. Piper Cancer Center study targets non-small cell lung cancer
Date:8/29/2012

SCOTTSDALE, Ariz. August 29, 2012 A Phase I/II, multi-center trial designed to test the safety and preliminary efficacy of a first in class cancer treatment opened worldwide today at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen). PR610 is designed to become activated in tissues with low levels of oxygen, which is characteristic of many cancers. This "targeted" approach should deliver more active drug to cancer tissue and less active drug to normal tissue.

The two-part trial, sponsored by the drug's manufacturer, Proacta Inc., will first determine acceptable dose levels of PR610 in patients with various types of advanced cancer. After determining acceptable dose levels, the study will evaluate the safety and efficacy of PR610 when given to patients with non-small cell lung cancer whose tumors contain a certain genetic mutation. Other goals of the study are to measure levels of PR610 in the blood.

"PR610 is a promising and innovative compound that merges delivery of a drug to the cancerous, oxygen depleted tissue and it also targets the communication functions that govern the growth and behavior that drive certain cancers," said Dr. Glen Weiss, Clinical Associate Professor at TGen and Director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare.

Research has shown that some cancer tissue has lower levels of oxygen than normal tissue. This lower level of oxygen appears to make the cancer tissue more resistant to radiation and chemotherapy, which allows the cancer to become more aggressive and spread. PR610 is designed to become active in cancer tissue with low levels of oxygen.

"Proacta is very excited to be working with Virginia G. Piper Cancer Center Clinical Trials and TGen on this important study. We purposely limited participation in this study to those cancer centers with extensive experience and expertise in conducting clinical oncology trials," said Dr. John Gutheil, CEO of Proacta.

Non-small cell lung cancer is a disease in which cancerous cells form in the tissues of the lung. There are several types, and chances of recovery are determined by many factors, such as smoking and lifestyle. Unfortunately, current treatments options do not cure the majority of patients with non-small cell lung cancer.

About 44 people will participate in this study at research sites in the U.S. and New Zealand, with the Virginia G. Piper Cancer Center at Scottsdale Healthcare being the first to enroll a patient.


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Healthy Back Store Confirms Closure of East Tyson’s Virginia Location
2. Could a cancer drug potentially prevent learning disabilities in some kids?
3. Aspirin may help men with prostate cancer live longer, study suggests
4. Race May Affect Quality of Prostate Cancer Surgical Care
5. Mayo study: Exercise can help cancer patients, but few oncologists suggest it
6. Exploring exercise benefits for breast cancer patients
7. Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
8. Breast Cancer Drug Might Help Men on Prostate Cancer Therapy
9. Reducing the side effects of treatment for prostate cancer
10. Accuracy of narrow band imaging with colonoscopy allows for distal non-cancerous polyps to be left in place
11. Daily Aspirin May Help Fight Prostate Cancer, But Not Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
Breaking Medicine Technology: